Gyroscope Capital Management Group LLC Acquires 4,483 Shares of Pfizer Inc. (NYSE:PFE)

Gyroscope Capital Management Group LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 48.2% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,787 shares of the biopharmaceutical company’s stock after buying an additional 4,483 shares during the period. Gyroscope Capital Management Group LLC’s holdings in Pfizer were worth $489,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Heritage Way Advisors LLC grew its position in shares of Pfizer by 0.6% in the second quarter. Heritage Way Advisors LLC now owns 57,524 shares of the biopharmaceutical company’s stock valued at $2,492,000 after purchasing an additional 354 shares during the last quarter. Natixis acquired a new position in shares of Pfizer in the second quarter valued at approximately $258,466,000. Machina Capital S.A.S. grew its position in Pfizer by 14.4% during the second quarter. Machina Capital S.A.S. now owns 43,837 shares of the biopharmaceutical company’s stock worth $1,899,000 after buying an additional 5,522 shares in the last quarter. M Holdings Securities Inc. grew its position in Pfizer by 27.9% during the first quarter. M Holdings Securities Inc. now owns 39,851 shares of the biopharmaceutical company’s stock worth $1,692,000 after buying an additional 8,693 shares in the last quarter. Finally, Integrated Wealth Concepts LLC grew its position in Pfizer by 14.2% during the second quarter. Integrated Wealth Concepts LLC now owns 68,060 shares of the biopharmaceutical company’s stock worth $2,840,000 after buying an additional 8,445 shares in the last quarter. Hedge funds and other institutional investors own 71.69% of the company’s stock.

In other Pfizer news, major shareholder Pfizer Inc bought 50,000 shares of Pfizer stock in a transaction on Tuesday, September 17th. The shares were purchased at an average price of $18.00 per share, with a total value of $900,000.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Scott Gottlieb bought 3,000 shares of Pfizer stock in a transaction on Friday, August 23rd. The stock was acquired at an average cost of $34.72 per share, for a total transaction of $104,160.00. Following the acquisition, the director now owns 3,000 shares in the company, valued at approximately $104,160. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.



A number of equities research analysts recently issued reports on PFE shares. Bank of America downgraded Pfizer from a “buy” rating to a “neutral” rating in a research report on Tuesday, July 30th. UBS Group reissued a “neutral” rating and set a $43.00 price target on shares of Pfizer in a research report on Monday, August 5th. JPMorgan Chase & Co. increased their price target on Pfizer from $37.00 to $46.00 and gave the stock a “neutral” rating in a research report on Thursday, September 19th. They noted that the move was a valuation call. ValuEngine raised Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, DZ Bank raised Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price target on the stock in a research report on Wednesday, August 28th. Twelve investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. Pfizer presently has an average rating of “Hold” and an average price target of $45.20.

Shares of PFE stock traded up $0.51 during trading hours on Friday, reaching $36.30. The company’s stock had a trading volume of 10,942,035 shares, compared to its average volume of 19,407,336. The firm’s 50 day simple moving average is $35.94 and its 200-day simple moving average is $39.97. The company has a market capitalization of $195.97 billion, a price-to-earnings ratio of 12.10, a PEG ratio of 2.82 and a beta of 0.66. Pfizer Inc. has a fifty-two week low of $33.97 and a fifty-two week high of $46.47. The company has a quick ratio of 1.21, a current ratio of 1.47 and a debt-to-equity ratio of 0.60.

Pfizer (NYSE:PFE) last issued its earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.05. The firm had revenue of $13.26 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. The company’s revenue was down 1.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.77 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.81 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a $0.36 dividend. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.97%. The ex-dividend date of this dividend is Thursday, November 7th. Pfizer’s dividend payout ratio is presently 48.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Article: What is a resistance level?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.